ACXP

Acurx Pharmaceuticals Inc. (ACXP) | Rumor.io

Acurx Pharmaceuticals

ACXP

Attention (50-day avg)0%

Attention rank (50-day avg)#3,157

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.25

Market capitalization5.8M

Earnings per share-2.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8M

Social

What share of all stock conversation is about ACXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Apr 16

Acurx Pharmaceuticals, Inc. (ACXP) has entered into a definitive agreement for a stock offering and warrants to support its growth strategy, with the sale of 825,000 shares of common stock priced at $3.03 per share and the issuance of short-term warrants covering up to 1.6 million additional shares.
The offering is expected to close in late April 2026 and is aimed at supporting the company's ongoing development of next-generation antibiotics for difficult-to-treat infections, with the proceeds to be used to fund the company's clinical trials and operations.
The company has announced up to $7.1 million registered direct offering priced at-the-market under Nasdaq rules, with the proceeds to be used to fund the development of its lead candidate, ibezapolstat, in the treatment of CDI.

Generated by AI

Sentiment

Of the messages about ACXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.45% +6.25
Bearish	—	—	—	14.55% -6.25

Bullish· Mar 19

$ACXP has the potential to reach $8.34, with a ton of selling at $7.17, indicating a strong base to break through.
Acquisition rumors are gaining traction, supported by strategic discussions in Acurx Pharmaceuticals' latest earnings call, leading to a surge in the stock price.
The stock has broken through key resistance levels, with high conviction and speculative play, indicating a possible vertical move with the right catalyst.

Bearish· Mar 13

Acurx Pharmaceuticals' stock price is expected to fall to $3.30 due to a potential offering.
The company's stock has a history of experiencing fake price pops followed by significant losses, with prices often returning to around $3.25.
Acurx Pharmaceuticals' stock is vulnerable to a sharp decline, potentially reaching as low as $2.50, if the company announces an offering at that price.

Generated by AI

Topics

Of the messages about ACXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	90%
Analysts	—	—	0%	8.1%
Controversies	—	—	0%	0.02%
Earnings	—	—	0%	0.01%
Macro	—	—	0%	0.38%
Technical Analysis	—	—	0%	1.49%

Announcements· Mar 19

Acurx Pharmaceuticals' stock surged due to acquisition rumors and strategic discussions in their latest earnings call, with some analysts considering it a high-conviction, speculative play.
The company's Q4 earnings call revealed a revenue beat against consensus estimates, signaling a potential inflection point for the clinical-stage biopharma, with some experts pointing to a significant partnership as a key to unlocking value.
Acurx Pharmaceuticals' shares surged following the signing of a new franchise agreement, as discussed in its recent earnings call, with some analysts highlighting improved capital allocation strategy and significant revenue growth as catalysts for the stock's performance.

Technical Analysis· Mar 19

Acurx Pharmaceuticals, Inc. ($ACXP) has broken through key resistance levels, with some posts citing specific price targets and momentum indicators.
The stock has seen significant volume and price movement, with some posts suggesting a strong technical breakout and potential continuation to new highs.
Post-earnings momentum has been cited as a key driver of the stock's recent move, with some posts highlighting the potential for further upside as the company's Q4 2025 earnings narrative continues to unfold.

Generated by AI

Community

Of the messages about ACXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	22.22%	4.53%
Newcomers	0%	0%	77.78%	95.47%

Regulars· Mar 10

The regulars are focusing on the stock's potential to break through resistance levels, with a key level of $3.08 and a target of $3.50.
The stock's low float is moving 41%, and the regulars are expecting a breakout as volume expands, with buyers dominating the tape and fuelling continuation.
The regulars are watching the stock's antibiotic development story for regulatory pathway updates or partnership chatter, and milestone timing clarity that could move the stock.

Newcomers· Mar 19

New traders are focusing on finding high-quality setups and taking aggressive trades on $ACXP, with some experiencing success and others facing losses.
The stock's recent price surge has caught the attention of newcomers, with some attributing the increase to a catalyst or analyst expectations, while others are simply enjoying the ride.
New investors are being reminded to participate in trading signals or to sell a portion of their $ACXP holdings, suggesting a sense of urgency and a desire to capitalize on the stock's momentum.

Generated by AI

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo

1d agoYahoo! Finance Canada

Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call

12d agoBenzinga

Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a late clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific poster entitled: Comparative In Vitro Killing Kinetics of Ibezapolstat and Comparator Antibiotics in Clostridioides difficile and Vancomycin-resistant Enterococcus Co-Cultures was presented at the 9th International C. difficile Symposium held in Bled, Slovenia from September 8-10, 2026. The

16d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Detailed price information for Annovis Bio Inc (ANVS-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Company advances toward pivotal Phase 3 trial with conditional FDA guidance, while securing funding to support operations for at least one year.

1mo agoYahoo Finance

Also Discussed

Investors talking about ACXP also mention

#	Name	Attention
1	Agape Atp CorpATPC	0%0
2	PTL Limited Class A Ordinary SharesPTLE	0%new
3	ULY - Urgent.ly Inc. Common Stock	——
4	DTCK - Davis Commodities Limited Ordinary Shares	——
5	BioAffinity Technologies Inc.BIAF	0%+0
6	Tradr 2X Long Innovation 100 Monthly ETFMQQQ	0%new
7	SECO - Secoo Holding Limited	——
8	Lakeland Financial Corp.LKFN	0%0
9	MKDWELL Tech Inc.MKDW	0%+0
10	LanzaTech Global Inc. Common StockLNZA	0%new

Acurx Pharmaceuticals Inc.

Healthcare
Biotechnology

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile. The company is also advancing ACX-375C, an antibiotic program intended to address resistant bacteria including MRSA, VRE, and drug-resistant Streptococcus pneumoniae. In addition to its lead and pipeline candidates, Acurx Pharmaceuticals Inc. works on anti-infective therapies for pathogens identified as priority threats by major public health agencies. The company operates in the biopharmaceutical sector, where its research is centered on unmet medical needs in infectious disease treatment and the development of new options for antibiotic-resistant infections.

Website

Location

259 Liberty Avenue

Staten Island, NY, 10305

United States

Social

What share of all stock conversation is about ACXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Apr 16

Acurx Pharmaceuticals, Inc. (ACXP) has entered into a definitive agreement for a stock offering and warrants to support its growth strategy, with the sale of 825,000 shares of common stock priced at $3.03 per share and the issuance of short-term warrants covering up to 1.6 million additional shares.
The offering is expected to close in late April 2026 and is aimed at supporting the company's ongoing development of next-generation antibiotics for difficult-to-treat infections, with the proceeds to be used to fund the company's clinical trials and operations.
The company has announced up to $7.1 million registered direct offering priced at-the-market under Nasdaq rules, with the proceeds to be used to fund the development of its lead candidate, ibezapolstat, in the treatment of CDI.

Generated by AI

Sentiment

Of the messages about ACXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.45% +6.25
Bearish	—	—	—	14.55% -6.25

Bullish· Mar 19

$ACXP has the potential to reach $8.34, with a ton of selling at $7.17, indicating a strong base to break through.
Acquisition rumors are gaining traction, supported by strategic discussions in Acurx Pharmaceuticals' latest earnings call, leading to a surge in the stock price.
The stock has broken through key resistance levels, with high conviction and speculative play, indicating a possible vertical move with the right catalyst.

Bearish· Mar 13

Acurx Pharmaceuticals' stock price is expected to fall to $3.30 due to a potential offering.
The company's stock has a history of experiencing fake price pops followed by significant losses, with prices often returning to around $3.25.
Acurx Pharmaceuticals' stock is vulnerable to a sharp decline, potentially reaching as low as $2.50, if the company announces an offering at that price.

Generated by AI

Topics

Of the messages about ACXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	90%
Analysts	—	—	0%	8.1%
Controversies	—	—	0%	0.02%
Earnings	—	—	0%	0.01%
Macro	—	—	0%	0.38%
Technical Analysis	—	—	0%	1.49%

Announcements· Mar 19

Acurx Pharmaceuticals' stock surged due to acquisition rumors and strategic discussions in their latest earnings call, with some analysts considering it a high-conviction, speculative play.
The company's Q4 earnings call revealed a revenue beat against consensus estimates, signaling a potential inflection point for the clinical-stage biopharma, with some experts pointing to a significant partnership as a key to unlocking value.
Acurx Pharmaceuticals' shares surged following the signing of a new franchise agreement, as discussed in its recent earnings call, with some analysts highlighting improved capital allocation strategy and significant revenue growth as catalysts for the stock's performance.

Technical Analysis· Mar 19

Acurx Pharmaceuticals, Inc. ($ACXP) has broken through key resistance levels, with some posts citing specific price targets and momentum indicators.
The stock has seen significant volume and price movement, with some posts suggesting a strong technical breakout and potential continuation to new highs.
Post-earnings momentum has been cited as a key driver of the stock's recent move, with some posts highlighting the potential for further upside as the company's Q4 2025 earnings narrative continues to unfold.

Generated by AI

Community

Of the messages about ACXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	22.22%	4.53%
Newcomers	0%	0%	77.78%	95.47%

Regulars· Mar 10

The regulars are focusing on the stock's potential to break through resistance levels, with a key level of $3.08 and a target of $3.50.
The stock's low float is moving 41%, and the regulars are expecting a breakout as volume expands, with buyers dominating the tape and fuelling continuation.
The regulars are watching the stock's antibiotic development story for regulatory pathway updates or partnership chatter, and milestone timing clarity that could move the stock.

Newcomers· Mar 19

New traders are focusing on finding high-quality setups and taking aggressive trades on $ACXP, with some experiencing success and others facing losses.
The stock's recent price surge has caught the attention of newcomers, with some attributing the increase to a catalyst or analyst expectations, while others are simply enjoying the ride.
New investors are being reminded to participate in trading signals or to sell a portion of their $ACXP holdings, suggesting a sense of urgency and a desire to capitalize on the stock's momentum.

Generated by AI

Acurx Pharmaceuticals

Social

Apr 16

Sentiment

Bullish· Mar 19

Bearish· Mar 13

Topics

Announcements· Mar 19

Technical Analysis· Mar 19

Community

Regulars· Mar 10

Newcomers· Mar 19

News

Acurx enrolls first patient in recurrent C. difficile trial

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Also Discussed

Acurx Pharmaceuticals Inc.

Company Information

Location

News

Acurx enrolls first patient in recurrent C. difficile trial

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Also Discussed

Social

Apr 16

Sentiment

Bullish· Mar 19

Bearish· Mar 13

Topics

Announcements· Mar 19

Technical Analysis· Mar 19

Community

Regulars· Mar 10

Newcomers· Mar 19